JCO precision oncology · 2026
Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yu-Wei, Xiu Joanne, Poorman Kelsey Anne, Ryan Charles J, Gilg Brady, Oberley Matthew James, Sura Gloria, Sledge George W, Zhao Shuang G, Tan Alan, Beltran Himisha, McKay Rana R
Аннотация
PURPOSE: This study aimed to define molecular subtypes of prostate cancer by integrating androgen receptor (AR) signaling, neuroendocrine prostate cancer (NEPC) transcriptional signatures, and genomic alterations to inform biomarker-driven therapies in metastatic castration-resistant prostate cancer.
METHODS: We analyzed 8,019 prostate tumors using DNA/RNA sequencing (Caris Life Sciences), classifying them into four molecular subtypes (AR+/NE-, AR-/NE+, AR+/NE+, AR-/NE-). Genomic alterations, cell surface target expression, and overall survival (OS) were evaluated.
RESULTS: Of the 8,019 tumors, 87.2% were adenocarcinoma, 1.9% NEPC, and 0.4% had mixed histology; 63% were from primary sites and 36.5% from metastases. The median age was 68 years; 63% were White, 15% Black, and 2.6% Asian or Pacific Islander. Most tumors were classified as AR+/NE- (91%), and 4.6% were AR-/NE+. TP53 and PTEN alterations were enriched in AR-negative subtypes, whereas SPOP mutations were more frequent in AR+ tumors. FOLH1 (prostate-specific membrane antigen) expression was the highest in AR+ tumors, whereas DLL3 expression was elevated in NE+ tumors. Median OS was significantly longer in tumors with high AR signaling (55.0 v 14.0 months, P < .00001) and lower with the NEPC signature (54.3 v 16.1 months, P < .00001). Combined stratification showed the most favorable outcome in AR+/NE- tumors (55.3 months) and the poorest in AR-/NE+ tumors (12.0 months).
CONCLUSION: Prostate cancer exhibits distinct molecular subtypes defined by AR signaling activity, NEPC transcriptional profiles, and genomic alterations. These biologically and clinically relevant subgroups provide a framework for precision oncology approaches and inform patient selection for biomarker-driven trials such as the ongoing PREDICT study (ClinicalTrials.gov identifier: NCT06632977).
METHODS: We analyzed 8,019 prostate tumors using DNA/RNA sequencing (Caris Life Sciences), classifying them into four molecular subtypes (AR+/NE-, AR-/NE+, AR+/NE+, AR-/NE-). Genomic alterations, cell surface target expression, and overall survival (OS) were evaluated.
RESULTS: Of the 8,019 tumors, 87.2% were adenocarcinoma, 1.9% NEPC, and 0.4% had mixed histology; 63% were from primary sites and 36.5% from metastases. The median age was 68 years; 63% were White, 15% Black, and 2.6% Asian or Pacific Islander. Most tumors were classified as AR+/NE- (91%), and 4.6% were AR-/NE+. TP53 and PTEN alterations were enriched in AR-negative subtypes, whereas SPOP mutations were more frequent in AR+ tumors. FOLH1 (prostate-specific membrane antigen) expression was the highest in AR+ tumors, whereas DLL3 expression was elevated in NE+ tumors. Median OS was significantly longer in tumors with high AR signaling (55.0 v 14.0 months, P < .00001) and lower with the NEPC signature (54.3 v 16.1 months, P < .00001). Combined stratification showed the most favorable outcome in AR+/NE- tumors (55.3 months) and the poorest in AR-/NE+ tumors (12.0 months).
CONCLUSION: Prostate cancer exhibits distinct molecular subtypes defined by AR signaling activity, NEPC transcriptional profiles, and genomic alterations. These biologically and clinically relevant subgroups provide a framework for precision oncology approaches and inform patient selection for biomarker-driven trials such as the ongoing PREDICT study (ClinicalTrials.gov identifier: NCT06632977).